operating-guidelines-dhbs-providers-covid-19-vaccine-immunisation-programme-08Mar2022 Final

Page 159

Appendix G: Vaccination site screening questions We encourage you to screen both staff and consumers for risk of exposure to COVID-19 and COVID-19 symptoms. Screening is critical to breaking the chain of transmission of COVID-19 and maintaining staff and consumer safety. Figure G.1 below details the recommended screening questions and process to create a lower risk environment for transmission of COVID-19 and to ensure PPE advice in Appendix K is appropriate. Please note: • • • •

In the event of COVID-19 Alert Level changes, additional advice will be formulated by local public health units and the Ministry. Any consumer with a confirmed COVID-19 infection should not be vaccinated until they have had the appropriate recovery period (see Immunisation Handbook or consult with IMAC). Any consumer that has answered ‘yes’ to the screening questions below, is considered high risk for the transmission of COVID-19 and deferral is recommended. If a provider wishes to vaccinate a higher risk consumer (someone who answered yes below), providers should follow the ‘vaccination in high-risk or screen ‘positive’ consumers’ section in the Operating Guidelines.

Figure G.1– recommended screening questions Q1 – Do you have symptoms of COVID-19? Follow link to COVID-19 Case definition

If a client has any symptoms suggestive of COVID-19, defer vaccination and do not permit entry to the site. Advise them to follow recommendations and guidance from the Ministry/public health services. Recommend they get a test and self-isolate pending the result. If no symptoms, continue to the next question.

Q2 – Do you live with someone who has COVID-19? If an individual lives with someone who has COVID-19, they are considered a household contact do not permit entry to the site and advise them to follow recommendations and guidance from the Ministry/public health services. If no symptoms, continue to the next question. Q3 – Have you been requested to stay at home, to self-isolate or are under an isolation order?

If yes, defer vaccination and do not permit entry to the site. Recommend continuing to follow the stay at home/self-isolation plan. If no symptoms, continue to the next question. Q4 – Are you currently waiting on a COVID-19 test result?

If yes, defer vaccination and do not permit entry to the site. Recommend rebooking once a negative test result has been received, and they have been told they no longer need to stay at home/self-isolate. If no, proceed to vaccinate as per the Operating Guidelines. Version 34.0 Page 159


Turn static files into dynamic content formats.

Create a flipbook

Articles inside

Appendix K: Vaccination practice variation according to the COVID-19 Protection Framework changes

5min
pages 168-169

Appendix G: Vaccination site screening questions

2min
page 159

Appendix J: Risk mitigations for vaccination sites

2min
page 167

Appendix E: CVIP logistics overview/cheat sheets

4min
pages 156-157

Appendix D: Logistics and inventory management

1min
page 155

Incidents

6min
pages 137-141

Variations

1min
page 142

Affected persons under the Vaccinations Order

4min
pages 128-130

National Immunisation Booking System

11min
pages 131-136

Home vaccinations

2min
pages 125-126

Mobile vaccination team

1min
page 124

COVID-19 Trial Vaccinations

1min
page 127

Vaccination in Hospital

1min
page 123

Vaccination and Surveillance Testing

1min
page 122

Third primary dose for severely immunocompromised

1min
page 121

Section F: Additional programme guidance, variations and incidents

1min
page 117

Vaccination in high-risk or screened ‘positive’ consumers

5min
pages 118-120

Novavax Operational phase

1min
page 108

Novavax Vaccine administration and observation

8min
pages 111-116

Novavax Preparation of doses

2min
pages 109-110

Booking and scheduling

1min
page 107

Section E: Novavax (Nuvaxovid) COVID-19 Vaccine

1min
page 106

AstraZeneca Vaccine administration and observation

8min
pages 100-105

AstraZeneca Preparation of doses

2min
pages 98-99

AstraZeneca Operational phase

1min
page 97

Paediatric Pfizer Vaccine administration and observation

9min
pages 89-94

Section D: AstraZeneca COVID-19 Vaccine

1min
page 95

Booking and scheduling

1min
page 96

Paediatric Pfizer Preparation of doses

3min
pages 86-88

Vaccine safety and additional considerations for consumers aged 5 to 11 years

1min
page 85

Pfizer Vaccine administration and observation

13min
pages 72-81

Booking and scheduling

3min
pages 62-64

Vaccinating consumers aged 12 to 15 years

1min
page 68

Pfizer Preparation of doses

4min
pages 69-71

Pfizer Operational phase

2min
pages 66-67

Protecting security and privacy

1min
page 65

Becoming a COVID-19 Vaccination site

1min
page 60

Site readiness and closure

1min
page 59

Disposal of consumables, vaccine, and vaccine packaging

2min
pages 57-58

COVID-19 Immunisation Register

3min
pages 29-31

Preparing the vaccination workforce

7min
pages 22-26

Infection prevention and control (IPC

2min
pages 27-28

Section A: Ready to vaccinate

1min
page 15

Site considerations

7min
pages 18-21

Equipment ordering and demand planning

7min
pages 33-38

Vaccine storage and handling

8min
pages 39-44

Logistics

1min
page 32
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.
operating-guidelines-dhbs-providers-covid-19-vaccine-immunisation-programme-08Mar2022 Final by WBOP PHO - Issuu